Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa

Arun C Inamadar

doi:10.1111/dth.14279

Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa

Dermatol Ther. 2020 Nov;33(6):e14279. doi: 10.1111/dth.14279. Epub 2020 Sep 15.

Author

Arun C Inamadar¹

Affiliation

¹ Department of Dermatology, SBMP Medical College Hospital & Research Center, BLDE University, Vijaypura, Karnataka, India.

PMID: 32888385
DOI: 10.1111/dth.14279

Abstract

A 6-year-old child with recessive dystrophic epidermolysis bullosa, confirmed by history, clinical exam, and antigen mapping, was treated with losartan with reduction in the blistering and better quality of life.

Keywords: epidermolysis bullosa; losartan; recessive dystrophic epidermolysis bullosa.

Publication types

Case Reports

MeSH terms

Child
Epidermolysis Bullosa Dystrophica* / diagnosis
Epidermolysis Bullosa Dystrophica* / drug therapy
Epidermolysis Bullosa Dystrophica* / genetics
Humans
Losartan / therapeutic use
Quality of Life

Substances

Losartan